2,6,9-Trisubstituted purine derivatives as protein A mimetics for the treatment of autoimmune diseases

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 1, 2009, Pages 242-246

  Zacharie, Boulos ^a   Fortin, Daniel ^a   Wilb, Nicole ^a   Bienvenu, Jean François ^a   Asselin, Michel ^a   Grouix, Brigitte ^a   Penney, Christopher ^a  

^a ProMetic Life Sciences Inc   (Canada)

Author keywords

Autoimmune diseases; IgG; Protein A mimetics; Purines

Indexed keywords

6 (3 AMINOPHENYLAMINO)PURINE DERIVATIVE; IMMUNOGLOBULIN G; METHOTREXATE; PROTEIN A; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; INFLAMMATION; MOUSE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULIN G; MOLECULAR MIMICRY; PURINES; STAPHYLOCOCCAL PROTEIN A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57849160167     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.116     Document Type: Article

References (28)

1. Advances in Immunology: Langone, J.J., Dixon, F.J., Kuhnel, H.G. Eds. New York, 1982, p. 157. Vol. 32.
2. Nilsson B., and Abrahmsén L. Methods Enzymol. 185 (1990) 144
3. Moks T., Abrahmsén L., Nilsson B., Hellman U., Sjoquist J., and Uhlén M. Eur. J. Biochem. 156 (1986) 637
4. Delano W., Ultsch M., de Vos A.M., and Wells J. Science 287 (2000) 1279 and references cited therein
5. Li R., Dowd V., Stewart D.J., Burton J., and Lowe C.R. Nat. Biotechnol. 16 (1998) 190
6. Fassina G., Ruvo M., Palombo G., Verdoliva A., and Marino M. J. Biochem. Biophys. Methods 49 (2001) 481
7. Godfrey M.A., Kwasowski P., Clift R., and Marks V. J. Immunol. Methods 160 (1993) 97
8. Fern Teng S., Sproule K., Hussain A., and Lowe C.R. J. Mol. Recognit. 12 (1999) 67
9. Delano W.L., Ultsch M.H., de Vos A.M., and Wells J.A. Science 287 (2000) 1279
10. Ehrlich G.K., and Bailon P. J. Biochem. Biophys. Methods 49 (2001) 443
11. Fassina G., Verdoliva A., Oderna M.R., Ruvo M., and Cassini G. J. Mol. Recognit. 9 (1996) 564
12. Johnson C.P., Jensen I.E., Prakasam A., Vijayendran R., and Leckband D. Bioconjugate Chem. 14 (2003) 974
13. Sasso E.H., Merrill C., and Furst D.E. Ther. Apher. 5 (2001) 84
14. Brunner J., Kern P.M., Gaipl U.S., Voll R.E., Kalden J.R., Wiesenhutter C.W., and Hermann M. Mod. Rheumatol. 15 (2005) 9
15. Silverman G., Goodyear C.S., and Siegel D.L. Transfusion 45 (2005) 274
16. Wright G.E. Acta Biochim. Pol. 43 (1996) 115
17. Lou B. Drug Discov. Today 24 (2001) 1288
18. Davis J.T. Angew. Chem., Int. Ed. 43 (2004) 668
19. Brændvang M., and Gundersen L.-L. Bioorg. Med. Chem. 15 (2007) 7144
20. Sabat M., VanRens J.C., Clark M.P., Brugel T.A., Maier J., Bookland R.G., Laufersweiler M.J., Laughlin S.K., Golebiowski A., De B., Hsieh L.C., Walter R.L., Mekel M.J., and Janusz M.J. Bioorg. Med. Chem. Lett. 16 (2006) 4360
21. Chang Y.-T., Gray N.S., Rosania G.R., Sutherlin D.P., Kwon S., Norman T.C., Sarohia R., Leost M., Meijer L., and Schultz P.G. Chem. Biol. 6 (1999) 361
22. Langli G., Gundersen L.-L., and Rise F. Tetrahedron 52 (1996) 5625
23. Gray N.S., Kwon S., and Schultz G.P. Tetrahedron Lett. 38 (1997) 1161
24. +).
25. Penney, C. et al. WO 2006/024175.
26. DTH (CD4) cells play an important role in regulating the intensity of the DTH response.
27. Oral administration of compound 14 was undertaken following the same protocol as Ref. 15 with the exception that compound 14 was orally administered at 50 or 150 mg/kg from day 0 to day 13.
28. Adjuvant-induced arthritis was induced in female Lewis rats by the injection of lyophilized Mycobacterium butyricum suspended in mineral oil into the footpad. The development of arthritis was monitored over a 3-week period post-adjuvant injection. Inflammation peaks at day 3 following the adjuvant administration. Immune activation appears around day 14. Compounds were injected iv day -3, -2 and -1 pre-adjuvant injection and at day 10, 11 and 12 post-adjuvant injection. Body weight was recorded. The arthritis index, which is a measure of inflammation (edema), redness, and stiffness of the articulations, was used to monitor the development of the disease. The degree of arthritis was determined by measuring two perpendicular diameters of the ankles in the mediolateral and dorsoventral planes using a caliper. Joint circumference in millimeters is then calculated using a geometric formula. Both the incidence and severity of the arthritis was evaluated. Incidence is defined as the number of rats with clinical evidence of joint inflammation during the study period.